Voyant Bio
Biotechnology Research
Unleashing effective immunity against cancer by rewiring immune-immune cell interactions.
About us
Cancer immunotherapy fails in 80% of patients due to break down in immune cell interactions. Voyant Bio has developed a spatial biology platform to enhance immunity against multiple cancers by rewiring immune cell interactions. Voyant’s platform has the potential to radically improve treatment efficacy for over a third of the patients who fail to respond to current cancer immunotherapies, representing an $100B+ opportunity.
- Website
-
https://voyant.bio
External link for Voyant Bio
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Type
- Privately Held
- Founded
- 2023
- Specialties
- scrnaseq, genomics, drug discovery, AI, ML, clinical trials, and molecular profiling